Sangamo Therapeutics, Inc.
13 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Previously recorded as Sangamo Biosciences, Inc. (to 2017)
25
Ending by 2030
May 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 4 fees due Nov 21 to 30, 2026 · next Nov 21
- 1 fee due Jan 9, 2027The maintenance fee for Engineered Zinc Finger Proteins Targeting 5-Enolpyruvyl SHIKIMATE-3-Phosphate Synthase Genes (US 10,344,289) comes due Jan 9, 2027. Unpaid by Jul 9, 2027, it lapses early.
- 6 fees due Feb 6 to 15, 2027 · next Feb 6
- 1 fee due Mar 10, 2027The maintenance fee for Methods and Compositions for Treating Hemophilia (US 10,407,476) comes due Mar 10, 2027. Unpaid by Sep 10, 2027, it lapses early.
- 8 fees due Apr 6 to 24, 2027 · next Apr 6
- 3 fees due May 12 to 28, 2027 · next May 12
- 7 fees due Jun 1 to 22, 2027 · next Jun 1
- 4 fees due Jul 2 to 21, 2027 · next Jul 2
- 5 fees due Aug 9 to 23, 2027 · next Aug 9
- 2 fees due Sep 5 to 30, 2027 · next Sep 5
- 3 fees due Oct 14 to 26, 2027 · next Oct 14
- 5 fees due Nov 5 to 14, 2027 · next Nov 5
Recent changes
- 3 of the patents on this record were granted since Aug 23, 2026
- Oct 27 US 12,774,475 Novel Compositions and Methods for Producing Recombinant Aav
- Oct 13 US 12,758,654 Methods and Compositions for the Treatment of Fabry Disease
- Sep 29 US 12,747,273 HTT repressors comprising a zinc-finger protein transcription factor.
- 6 terms have ended since Aug 23, 2026
- Oct 30 US 10,113,207 Methods and Compositions for Targeted Single-Stranded Cleavage and Targeted Integration · lapsed on the fee record
- Sep 23 US 8,841,260 Methods and Compositions for Treating Huntington's Disease · lapsed on the fee record
- Sep 11 US 10,072,066 Methods and Compositions for Treatment of a Beta Thalessemia · lapsed on the fee record
- Sep 11 US 10,072,062 Methods and Compositions for Modification of a Hla Locus · lapsed on the fee record
- Sep 2 US 8,822,221 Targeted Integration into the PPP1R12C Locus · lapsed on the fee record
- Aug 23 US 7,795,209 Anti-Angiogenic Methods and Compositions · term ended
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,648,267 | Methods and Compositions for Gene Inactivation In force · Low confidence | In force | Low confidence | |
| US 10,717,993 | Methods and compositions for increased transgene expression In force · USPTO record | In force | USPTO record | |
| US 7,972,854 | Methods and Compositions for Targeted Cleavage and Recombination In force · High confidence | In force | High confidence | |
| US 11,884,930 | Method of Inactivating a Glucocorticoid Receptor Gene in an Isolated Cell In force · High confidence | In force | High confidence | |
| US 7,914,796 | Engineered Cleavage Half-Domains In force · High confidence | In force | High confidence | |
| US 9,045,763 | Linear donor constructs for targeted integration In force · Medium confidence | In force | Medium confidence | |
| US 9,267,154 | Targeted Integration into the PPP1R12C Locus In force · High confidence | In force | High confidence | |
| US 11,649,468 | Targeted Integration into the PPP1R12C Locus In force · High confidence | In force | High confidence | |
| US 8,110,379 | Targeted Integration into the PPP1R12C Locus In force · High confidence | In force | High confidence | |
| US 9,322,036 | Methods and Compositions for Inactivating Alpha 1,6 Fucosyltransferase (FUT8) Gene Expression In force · High confidence | In force | High confidence |
Also on record, not counted in the 139: 13 patents in force now held by others · 57 lapsed for an unpaid fee · 20 ended at full term · 2 past the fee grace period. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
20 pending · 40 abandoned · 10 no status recorded